# Epic Bio (Epicrispr Biotechnologies, Inc.)

> Clinical-stage genetic medicines company in South San Francisco, California, founded
> in 2018 by Stanford CRISPR pioneer Stanley Qi, Ph.D. Epic Bio develops epigenetic
> editing therapies that modulate gene expression without cutting DNA, using its
> proprietary Gene Expression Modulation System (GEMS) platform. Lead program EPI-321
> is in first-in-human clinical study for facioscapulohumeral muscular dystrophy (FSHD).

<!--
generated: '2026-08-12'
method: generated
source: apis.yml + repo artifacts (the provider publishes no llms.txt; https://epicrispr.com/llms.txt -> 404)
-->

## Important disambiguation

Epic Bio is **not** Epic Systems (the healthcare EHR vendor behind `open.epic.com` and
its FHIR APIs), and it is **not** the "Epic" application at `epic.bio`, which belongs to
Guerbet. Do not attribute any of those APIs to this company.

## API surface

**There is none.** Epic Bio is a therapeutics developer, not a software vendor. As of
2026-08-12 it publishes no public API, no SDK, no webhooks, no developer portal, no
machine-readable specification, and no GitHub organization. See `openapi/README.md` in
this repository for the full contract-discovery probe table (every probe returned 404 or
NXDOMAIN).

## Technology platform (scientific, not developer-facing)

- Gene Expression Modulation System (GEMS): a DNA-binding protein + tailored guide RNA +
  modulator protein, delivered without double-strand DNA breaks.
- DNA-binding proteins: CasMINI (exclusively licensed; among the smallest dCas proteins
  shown to work in human cells) and proprietary variants including CasONYX.
- Modulators: activators, repressors, histone modifiers, DNA methylators and chromatin
  remodelers.
- Guide RNAs: identified by a functional screening platform with proprietary computational
  design methods. Internal R&D tooling — not exposed publicly.

## Pipeline

- EPI-321 — facioscapulohumeral muscular dystrophy (FSHD) — first-in-human clinical study;
  enrollment and dose escalation completed.
- Alpha-1 antitrypsin deficiency (A1AD) — preclinical.
- Heterozygous familial hypercholesterolemia (HeFH) — preclinical.

## Public pages

- [Website](https://epicrispr.com/): corporate home.
- [Platform](https://epicrispr.com/platform/): the GEMS platform.
- [Science](https://epicrispr.com/science/): epigenetic editing approach.
- [Pipeline](https://epicrispr.com/pipeline/): programs and stages.
- [News](https://epicrispr.com/news/): press releases ([RSS](https://epicrispr.com/feed/)).
- [Team](https://epicrispr.com/team/): leadership and board.
- [For patients and caregivers](https://epicrispr.com/for-patients-and-caregivers/).
- [Expanded access policy](https://epicrispr.com/expanded-access-policy/).
- [Careers](https://epicrispr.com/careers/).
- [Contact](https://epicrispr.com/contact/).
- [Privacy policy](https://epicrispr.com/privacy-policy/).

## Repository artifacts

- `openapi/README.md`: contract-discovery probe record (no spec exists).
- `well-known/epic-bio-well-known.yml`: `/.well-known/*` probe record (all 404).
- `security/epic-bio-domain-security.yml`: TLS/HSTS/DNSSEC/CAA/SPF/DMARC probe.